INTERLEUKIN 5 BINDENDES PROTEIN-DOSIERUNGSREGELN

European patent · EP4267184 · Deleted

Register entry

Publication number
EP4267184
Application number
EP21844228
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Granted
Filed
Dec 20, 2021
Published
Nov 1, 2023
Granted
Nov 26, 2025
Deleted
Jul 23, 2026
Reason
Annual fee unpaid
IPC classes
A61K 39/395 (2006.01)
C07K 16/24 (2006.01)
Priority
US 202063128922 P 22.12.2020
US 202163192854 P 25.05.2021
US 202163220182 P 09.07.2021
US 202163285513 P 03.12.2021
PCT application
PCT/EP2021/086689 20.12.2021
PCT publication
WO2022/136209 30.06.2022
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 7, 2026

    Change

    Published in Swissreg on 07.10.2026

  2. Jul 23, 2026

    Deleted, fee unpaid

    Status of protective title
    Active → Cancelled
    Cancellation date
    23.07.2026
    Cause for cancellation
    Non-payment of renewal fee

    Published in Swissreg on 23.07.2026

  3. Nov 26, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 26.11.2025

Parties

Holder

GlaxoSmithKline Intellectual Property Development Limited

GSK Medicines Research Centre Gunnels Wood Road, Stevenage SG1 2NY, GB

Inventor

AUSTIN, Daren J

Brentford Middlesex TW8 9GS, GB

BIRD, Nicholas P

Stevenage Hertfordshire SG1 2NY, GB

MONCK, Myrna A

Collegeville, Pennsylvania 19426, US

POULIQUEN, Isabelle J

Brentford Middlesex TW8 9GS, GB

SHUMAN, Melissa A

Collegeville, Pennsylvania 19426, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.